Sunday, March 13, 2011

Baladex




Baladex may be available in the countries listed below.


Ingredient matches for Baladex



Guaifenesin

Guaifenesin is reported as an ingredient of Baladex in the following countries:


  • Poland

Theophylline

Theophylline is reported as an ingredient of Baladex in the following countries:


  • Poland

International Drug Name Search

Posted by at No comments:
Labels:

Vesanoïd




Vesanoïd may be available in the countries listed below.


Ingredient matches for Vesanoïd



Tretinoin

Tretinoin is reported as an ingredient of Vesanoïd in the following countries:


  • France

International Drug Name Search

Posted by at No comments:
Labels:

Propafenone




In the US, Propafenone (propafenone systemic) is a member of the drug class group I antiarrhythmics and is used to treat Atrial Fibrillation, Atrial Flutter, Ventricular Tachycardia and Wolff-Parkinson-White Syndrome.

US matches:

  • Propafenone

  • Propafenone Sustained-Release Capsules

  • Propafenone Hydrochloride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

C01BC03

CAS registry number (Chemical Abstracts Service)

0054063-53-5

Chemical Formula

C21-H27-N-O3

Molecular Weight

341

Therapeutic Category

Antiarrhythmic agent

Chemical Name

1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl-

Foreign Names

  • Propafenonum (Latin)
  • Propafenon (German)
  • Propafénone (French)
  • Propafenona (Spanish)

Generic Names

  • Propafenone (OS: BAN, DCIT)
  • Propafénone (OS: DCF)
  • Propafenone Hydrochloride (OS: BANM, USAN, JAN)
  • Fenopraine hydrochloride (IS)
  • SA 79 (IS)
  • WZ 88462-3 (IS)
  • Propafenone Hydrochloride (PH: BP 2010, Ph. Eur. 6, USP 32)
  • Propafenoni hydrochloridum (PH: Ph. Eur. 6)

Brand Names

  • Polfenon
    Polpharma, Poland


  • Propafenon Hexal
    Hexal, Luxembourg


  • Propafenonã
    Arena, Romania


  • Propafenon-Hexal
    Hexal, Luxembourg


  • Rytmonorm
    Abbott, Germany


  • Apo-Propafenone
    Apotex, Canada


  • Arythmol
    Abbott, United Kingdom; Abbott, Ireland


  • Cardiofenone
    Polifarma, Italy


  • Cuxafenon
    TAD, Germany


  • Fenorit
    Scharper, Italy


  • Gen-Propafenone
    Genpharm, Canada


  • Nistaken
    Kendrick, Mexico


  • Normorytmin
    Abbott, Argentina


  • Profenan
    Slaviamed, Serbia


  • Profex
    Taro, Israel


  • Prolekofen
    Lek, Czech Republic; Sandoz, Slovakia


  • Pronon
    Astellas, Japan


  • Propafen
    Heimdall, Colombia; Zorka, Serbia


  • Propafenon AL
    Aliud, Czech Republic; Aliud, Germany; Aliud, Hungary; Aliud, Romania


  • Propafenon Alkaloid
    Alkaloid, Croatia (Hrvatska)


  • Propafenon Genericon
    Genericon, Croatia (Hrvatska)


  • Propafenon HCl PCH
    Pharmachemie, Netherlands


  • Propafenon Heumann
    Heumann, Germany


  • Propafenon Hexal
    Hexal, Germany


  • Propafenon Pharmavit
    Walmark, Hungary


  • Propafenon Sandoz
    Sandoz, Germany


  • Propafenon Siga
    Sigapharm, Germany


  • Propafenon Stada
    Stada, Germany


  • Propafenon
    Alkaloid, Serbia; Alkaloid, Slovenia; Genericon, Austria


  • Propafenon-CT
    CT Arzneimittel, Germany


  • Propafenone Alter
    Alter, Italy


  • Propafenone DOC
    DOC Generici, Italy


  • Propafenone Hydrochloride
    Ethex, United States; KV Pharmaceutical, United States; Mutual, United States; Pliva, United States; Qualitest, United States; United Research, United States; URL, United States; Vintage, United States; Watson, United States


  • Propafenone Pensa
    Pensa, Italy


  • Propafenone ratiopharm
    Ratiopharm, Italy


  • Propafenone Sandoz
    Sandoz, Italy


  • Propafenon-ratiopharm
    Ratiopharm, Germany


  • Propanorm
    Pro.Med.CS, Bosnia & Herzegowina; Pro.Med.CS, Czech Republic; Pro.Med.CS, Estonia; Pro.Med.CS, Georgia; Pro.Med.CS, Lithuania; Pro.Med.CS, Russian Federation; Pro.Med.CS, Slovakia


  • Ritmocor
    Drugtech-Recalcine, Chile


  • Ritmonorm
    Knoll, Brazil


  • Ropaful
    Choseido Pharmaceutical, Japan


  • Rythmex
    Teva, Israel


  • Rythmol
    Abbott, Canada; Abbott, France; Abbott, South Africa; GlaxoSmithKline, United States


  • Rytmocard
    Abbott, Philippines; Sopharma, Bulgaria


  • Rytmonorm
    Abbott, Bosnia & Herzegowina; Abbott, Belgium; Abbott, Bulgaria; Abbott, Switzerland; Abbott, China; Abbott, Colombia; Abbott, Costa Rica; Abbott, Czech Republic; Abbott, Germany; Abbott, Denmark; Abbott, Estonia; Abbott, Spain; Abbott, Finland; Abbott, Georgia; Abbott, Guatemala; Abbott, Hong Kong; Abbott, Honduras; Abbott, Croatia (Hrvatska); Abbott, Hungary; Abbott, Indonesia; Abbott, Iceland; Abbott, Italy; Abbott, Lithuania; Abbott, Luxembourg; Abbott, Latvia; Abbott, Nicaragua; Abbott, Netherlands; Abbott, New Zealand; Abbott, Panama; Abbott, Peru; Abbott, Poland; Abbott, Portugal; Abbott, Romania; Abbott, Russian Federation; Abbott, Sweden; Abbott, Singapore; Abbott, Slovenia; Abbott, Slovakia; Abbott, El Salvador; Abbott, Thailand; Abbott, Turkey; Abbott, Taiwan; Abbott, Venezuela; Ebewe, Bulgaria; Ebewe, Romania; Knoll, United Arab Emirates; Knoll, Bahrain; Knoll, Egypt; Knoll, Iran; Knoll, Jordan; Knoll, Kuwait; Knoll, Lebanon; Knoll, Qatar; Knoll, Saudi Arabia


  • Rytmonorma
    Abbott, Austria


  • Rytmo-Puren
    Actavis, Germany


  • Sobiral
    Ohara Yakuhin, Japan

International Drug Name Search

Glossary

BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.
Posted by at No comments:
Labels:

Saturday, March 12, 2011

Leucodar




Leucodar may be available in the countries listed below.


Ingredient matches for Leucodar



Fluconazole

Fluconazole is reported as an ingredient of Leucodar in the following countries:


  • Bangladesh

International Drug Name Search

Posted by at No comments:
Labels:

Friday, March 11, 2011

Tyvaso


Tyvaso is a brand name of treprostinil, approved by the FDA in the following formulation(s):


TYVASO (treprostinil sodium - solution; inhalation)



  • Manufacturer: UNITED THERAP

    Approval date: July 30, 2009

    Strength(s): EQ 0.6MG BASE/ML [RLD]

Has a generic version of Tyvaso been approved?


No. There is currently no therapeutically equivalent version of Tyvaso available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyvaso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Method of treating pulmonary hypertension with benzidine prostaglandins
    Patent 5,153,222
    Issued: October 6, 1992
    Inventor(s): Tadepalli; Anjaneyulu S. & Long; Walker A. & Crow; James W. & Klein; Kenneth B.
    Assignee(s): Burroughs Wellcome Co.
    The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --; R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, or R is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; and the dotted line represents an optional double bond; or of a physiologically acceptable salt or acid derivative thereof. Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
    Patent expiration dates:

    • October 16, 2014
      ✓ 
      Patent use: TREATMENT OF PULMONARY HYPERTENSION




  • Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
    Patent 6,521,212
    Issued: February 18, 2003
    Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
    Assignee(s): United Therapeutics Corporation
    A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
    Patent expiration dates:

    • November 13, 2018
      ✓ 
      Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION




  • Method for delivering benzindene prostaglandins by inhalation
    Patent 6,756,033
    Issued: June 29, 2004
    Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
    Assignee(s): United Therapeutics Corporation
    A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
    Patent expiration dates:

    • November 13, 2018
      ✓ 
      Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION




  • Process for stereoselective synthesis of prostacyclin derivatives
    Patent 6,765,117
    Issued: July 20, 2004
    Inventor(s): Robert M.; Moriarty & Raju; Penmasta & Liang; Guo & Munagala S.; Rao & James P.; Staszewski
    Assignee(s): United Therapeutic Corporation
    An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. The invention also relates to novel intermediates prepared during the synthesis of the 9-deoxy-PGF1-type compounds.
    Patent expiration dates:

    • October 24, 2017
      ✓ 
      Drug substance



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 30, 2012 - NEW DOSAGE FORM

    • July 30, 2016 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Tyvaso Consumer Information (Drugs.com)
  • Tyvaso Inhalation Solution Consumer Information (Wolters Kluwer)
  • Tyvaso Consumer Information (Cerner Multum)
  • Tyvaso Refill Kit Consumer Information (Cerner Multum)
  • Tyvaso Starter Kit Consumer Information (Cerner Multum)
  • Tyvaso Advanced Consumer Information (Micromedex)
  • Treprostinil Inhalation Solution Consumer Information (Wolters Kluwer)
  • Treprostinil Solution Consumer Information (Wolters Kluwer)
  • Treprostinil Consumer Information (Cerner Multum)
  • Treprostinil inhalation Consumer Information (Cerner Multum)
  • Treprostinil injection Consumer Information (Cerner Multum)
  • Treprostinil Inhalation Advanced Consumer Information (Micromedex)
  • Treprostinil Injection Advanced Consumer Information (Micromedex)
  • Treprostinil Sodium AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Monday, March 7, 2011

Cisplatine Mayne




Cisplatine Mayne may be available in the countries listed below.


Ingredient matches for Cisplatine Mayne



Cisplatin

Cisplatin is reported as an ingredient of Cisplatine Mayne in the following countries:


  • Luxembourg

International Drug Name Search

Posted by at No comments:
Labels:

Sunday, March 6, 2011

Nongonococcal Urethritis Medications


Definition of Nongonococcal Urethritis: Urethritis not resulting from gonococcal infection. Venereally transmitted Chlamydia trachomatis is the most common cause.

Drugs associated with Nongonococcal Urethritis

The following drugs and medications are in some way related to, or used in the treatment of Nongonococcal Urethritis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Nongonococcal Urethritis

Medical Encyclopedia:

  • Chlamydial urethritis - male




Drug List:

Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)